Literature DB >> 10365880

Benefits and safety of hepatic resection for colorectal metastases.

K E Harmon1, J A Ryan, T R Biehl, F T Lee.   

Abstract

BACKGROUND: Metastatic colorectal carcinoma to the liver is a potentially curable disease. The purpose of this study was to determine the safety and efficacy of hepatic resection for metastatic colorectal carcinoma.
METHODS: One hundred twenty-one consecutive hepatic resections in 110 patients with metastatic colorectal cancer between January 1978 and September 1998 performed by a single surgeon were reviewed.
RESULTS: The actuarial 5-year survival for all patients in the series was 46%. Of the patients operated on before 1993, the actual 5-year survival was 43% and actual disease-free 5-year survival was 28%. The actual 10-year survival was 27%, and of all patients operated on in the last 20 years, 48% are alive today. When comparing initial regional lymph node status, the 5-year survival was 54% for the patients with negative lymph nodes and 40% for patients with positive nodes. Only 18% of patients required a perioperative blood transfusion, and the median length of stay was 7 days. There were complications in 34% of cases, and the operative mortality was 4%.
CONCLUSIONS: Hepatic resection for metastatic colon cancer is safe, and significant longevity and cure can be obtained after resection.

Entities:  

Mesh:

Year:  1999        PMID: 10365880     DOI: 10.1016/s0002-9610(99)00070-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  23 in total

Review 1.  Surveillance of patients following surgery with curative intent for colorectal cancer.

Authors:  Steven Gan; Katherine Wilson; Paul Hollington
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

2.  Radiofrequency-assisted liver resection.

Authors:  Mattia Stella; Andrea Percivale; Massimo Pasqualini; Alberto Profeti; Nicola Gandolfo; Giovanni Serafini; Riccardo Pellicci
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

3.  Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation.

Authors:  K A Patel; N D Edmondson; F Talbot; M A Parsons; I G Rennie; K Sisley
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

4.  Ruminations of an ordinary hepatic surgeon: a journey through the pitfalls of major liver resections.

Authors:  Thomas S Helling
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

5.  Current perioperative outcomes for patients with disseminated cancer.

Authors:  Sarah B Bateni; Frederick J Meyers; Richard J Bold; Robert J Canter
Journal:  J Surg Res       Date:  2015-03-27       Impact factor: 2.192

6.  A multicentre controlled study of the InLine radiofrequency ablation device for liver transection.

Authors:  Peng Yao; Frank Chu; Steve Daniel; Aravin Gunasegaram; Tristan Yan; Werner Lindemann; Georg Pistorius; Martin Schilling; Junji Machi; Randall Zuckerman; David L Morris
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  An Electrode Array for Limiting Blood Loss During Liver Resection: Optimization via Mathematical Modeling.

Authors:  R M Strigel; D J Schutt; J G Webster; D M Mahvi; D Haemmerich
Journal:  Open Biomed Eng J       Date:  2010-02-04

8.  Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome.

Authors:  Adriano Tocchi; Gianluca Mazzoni; Stefania Brozzetti; Michelangelo Miccini; Diletta Cassini; Elia Bettelli
Journal:  Int J Colorectal Dis       Date:  2004-04-22       Impact factor: 2.571

9.  Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.

Authors:  Srinevas K Reddy; Gloria Broadwater; Donna Niedzwiecki; Andrew S Barbas; Herbert I Hurwitz; Johanna C Bendell; Michael A Morse; Bryan M Clary
Journal:  J Gastrointest Surg       Date:  2008-08-07       Impact factor: 3.452

10.  Liver resection for breast cancer metastasis: does it improve survival?

Authors:  Jean Lubrano; Horace Roman; Sophie Tarrab; Benoit Resch; Loïc Marpeau; Michel Scotté
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.